{"id":1879,"date":"2024-03-27T14:21:28","date_gmt":"2024-03-27T14:21:28","guid":{"rendered":"https:\/\/stoxpo.com\/?p=1879"},"modified":"2024-03-27T14:21:30","modified_gmt":"2024-03-27T14:21:30","slug":"lixte-biotechnologys-lb-100-unveils-novel-cancer-treatment-strategy","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2024\/03\/27\/lixte-biotechnologys-lb-100-unveils-novel-cancer-treatment-strategy\/","title":{"rendered":"LIXTE Biotechnology&#8217;s LB-100 Unveils Novel Cancer Treatment Strategy"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\">Pre-clinical Data Shows Potential to Force Cancer Cells into Less Malignant States<\/h4>\n\n\n\n<p>LIXTE Biotechnology Holdings, Inc. has made a groundbreaking advancement in cancer treatment with its lead clinical compound, LB-100, as revealed in a recent publication in Cancer Discovery. The pre-clinical data highlights LB-100&#8217;s ability to induce cancer cells to relinquish their cancer-causing properties, presenting a promising new avenue in cancer therapy.<\/p>\n\n\n\n<p>LB-100 demonstrated a paradoxical effect by hyper-activating signals responsible for the uncontrolled proliferation of cancer cells, unlike conventional cancer treatments. When combined with a WEE1 kinase inhibitor, this approach proved highly effective in eliminating colon cancer cells in animal models and cell cultures, offering a potential solution to therapy resistance\u2014a major challenge in cancer treatment.<\/p>\n\n\n\n<p>Moreover, LB-100-induced resistance was associated with cancer cells adopting less malignant behaviors, inhibiting tumor formation in experimental models. This unique mechanism, coined &#8220;tumor suppressive drug resistance,&#8221; presents a novel concept in cancer therapy.<\/p>\n\n\n\n<p>Led by Professor Ren\u00e9 Bernards, a renowned figure in molecular carcinogenesis, the research team&#8217;s findings open new horizons for cancer treatment. LIXTE&#8217;s CEO, Bas van der Baan, expressed optimism about clinically testing LB-100&#8217;s unique approach, marking a significant departure from conventional cancer therapies.<\/p>\n\n\n\n<p>Read original press release:<a href=\"https:\/\/finance.yahoo.com\/news\/scientific-publication-shows-lb-100-123000894.html\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">here<\/mark><\/a><\/p>\n\n\n\n<p>You might like this article:<a href=\"https:\/\/stoxpo.com\/index.php\/2024\/03\/27\/moderna-unveils-promising-new-vaccine-candidates-beyond-covid\/\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">Moderna Unveils Promising New Vaccine Candidates Beyond COVID<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pre-clinical Data Shows Potential to Force Cancer Cells into Less Malignant States LIXTE Biotechnology Holdings, Inc. has made a groundbreaking advancement in cancer treatment with its lead clinical compound, LB-100, as revealed in a recent publication in Cancer Discovery. The pre-clinical data highlights LB-100&#8217;s ability to induce cancer cells to relinquish their cancer-causing properties, presenting [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1422,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jnews-multi-image_gallery":[],"jnews_single_post":{"subtitle":"","format":"standard","video":"","gallery":"","source_name":"","source_url":"","via_name":"","via_url":"","override_template":"0","override":[{"template":"8","single_blog_custom":"","parallax":"1","fullscreen":"1","layout":"right-sidebar-narrow","sidebar":"author","second_sidebar":"single-right","sticky_sidebar":"1","share_position":"top","share_float_style":"share-monocrhome","show_share_counter":"0","show_view_counter":"0","show_featured":"1","show_post_meta":"1","show_post_author":"1","show_post_author_image":"1","show_post_date":"1","post_date_format":"default","post_date_format_custom":"Y\/m\/d","show_post_category":"1","show_post_reading_time":"1","post_reading_time_wpm":"300","show_zoom_button":"0","zoom_button_out_step":"2","zoom_button_in_step":"3","show_post_tag":"1","show_prev_next_post":"1","show_popup_post":"1","number_popup_post":"1","show_author_box":"1","show_post_related":"1","show_inline_post_related":"0"}],"override_image_size":"0","image_override":[{"single_post_thumbnail_size":"crop-500","single_post_gallery_size":"crop-500"}],"trending_post":"0","trending_post_position":"meta","trending_post_label":"Trending","sponsored_post":"0","sponsored_post_label":"Sponsored by","sponsored_post_name":"","sponsored_post_url":"","sponsored_post_logo_enable":"0","sponsored_post_logo":"","sponsored_post_desc":"","disable_ad":"0"},"jnews_primary_category":{"id":"","hide":""},"jnews_social_meta":{"fb_title":"","fb_description":"","fb_image":"","twitter_title":"","twitter_description":"","twitter_image":""},"jnews_override_counter":{"override_view_counter":"0","view_counter_number":"0","override_share_counter":"0","share_counter_number":"0","override_like_counter":"0","like_counter_number":"0","override_dislike_counter":"0","dislike_counter_number":"0"},"jnews_post_split":{"enable_post_split":"0","post_split":[{"template":"1","tag":"h2","numbering":"asc","mode":"normal","first":"0","enable_toc":"0","toc_type":"normal"}]}},"categories":[308,358],"tags":[],"coauthors":[453],"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/1879"}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=1879"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/1879\/revisions"}],"predecessor-version":[{"id":1880,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/1879\/revisions\/1880"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/1422"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=1879"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=1879"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=1879"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=1879"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}